|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia.
|
21426550 |
2011 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52).
|
19924443 |
2010 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A significant association between Ala499Val polymorphism and bladder cancer was observed (OR = 1.78, CI = 1.19-2.66, p = 0.005); however, Lys939Gln was unrelated (OR = 0.97, CI = 0.65-1.45, P = 0.89).
|
27246180 |
2016 |
|
rs2228001
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
The aim of this meta-analysis is to generate large-scale evidence to determine the degree to which common Cyclin D1 (CCND1) G870A (dbSNP: rs603965) and xeroderma pigmentosum group C (XPC) Ala499Val (dbSNP: rs2228000) polymorphisms are associated with susceptibility to bladder cancer.
|
24264314 |
2014 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Likewise, Ala499Val was also significantly associated with an increased overall cancer risk (Val/Val vs. Ala/Ala: OR = 1.21, 95% CI = 1.07 - 1.36, p = 0.003 and recessive model: OR = 1.20, 95% CI = 1.08 - 1.34, p = 0.001) and further stratification showed an increased risk for breast and bladder cancer, particularly in Asian populations.
|
23400628 |
2013 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
The results for Ala499Val showed a significant overall increase in cancer risk (OR 1.15; 95% CI: 1.02-1.31), and for bladder cancer in both the simple genetic model (Ala/Ala vs Val/Val) (OR 1.30; 95% CI: 1.04-1.61) and the recessive genetic model (Ala/Ala+Ala/Val vs Val/Val) (OR 1.32; 95% CI: 1.06-1.63).
|
18285822 |
2008 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Individuals homozygous for the variant allele of XPC c.1496C > T (p.Ala499Val) were shown in a large pooled analysis to have an increased bladder cancer risk, and we found two 3'UTR variants, *611T > A and c.*618A > G, to be in strong linkage disequilibrium with c.1496T.
|
21689419 |
2011 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Numerous studies have investigated the association between three polymorphisms (Lys939Gln, Ala499Val and PAT-/+) of Xeroderma pigmentosum group C (XPC) gene and bladder cancer susceptibility; however, the findings are inconclusive.
|
23918308 |
2014 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We investigated three polymorphisms of the XPC gene (PAT, Ala499Val and Lys939Gln) in 600 subjects with bladder cancer and in 609 healthy controls by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay in a Chinese Han population.
|
22505326 |
2012 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We analyzed the associations of the genotypes, haplotypes and diplotypes of three XPC polymorphisms, Ala499Val (C-->T), PAT (-/+) and Lys939Gln (A-->C), with the risk of bladder cancer.
|
17052994 |
2007 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Individuals homozygous for the minor allele of Ala(499)Val, Ex15-184, or Ex15-177 had an increased risk of bladder cancer compared with those homozygous for the common allele [adjusted odds ratio (95% confidence interval), 1.65 (1.05-2.59), 1.82 (1.12-2.97), and 1.82 (1.12-2.96), respectively].
|
17164382 |
2006 |
|
rs2228000
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
A significant association between Ala499Val polymorphism and bladder cancer was observed (OR = 1.78, CI = 1.19-2.66, p = 0.005); however, Lys939Gln was unrelated (OR = 0.97, CI = 0.65-1.45, P = 0.89).
|
27246180 |
2016 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
In this study, it was hypothesized that MTHFR (C677T and A1298C) polymorphisms would be associated with bladder cancer and also with hypermethylation of the promoter of the Ras association domain family 1A (RASSF1A) gene.
|
20146887 |
2010 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
We hypothesized that the MTHFR C677T, A1298C, and MS A2756G polymorphisms are associated with risk of bladder cancer.
|
18815869 |
2009 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Assuming a very low prior probability of 0.000001, similar to a probability assumed for a randomly selected single-nucleotide polymorphism in a genome-wide association study, and statistical power to detect an OR of 1.5, 4 associations were considered noteworthy as denoted by an FPRP value <0.2: GSTM1 null and bladder cancer (OR, 1.5; 95% CI, 1.3-1.6; P = 1.9 x 10(-14)), NAT2 slow acetylator and bladder cancer (OR, 1.46; 95% CI, 1.26-1.68; P = 2.5 x 10(-7)), MTHFR C677T and gastric cancer (OR, 1.52; 95% CI, 1.31-1.77; P = 4.9 x 10(-8)), and GSTM1 null and acute leukemia (OR, 1.20; 95% CI, 1.14-1.25; P = 8.6 x 10(-15)).
|
18505952 |
2008 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
To clarify the role of MTHFR polymorphisms on bladder cancer risk, we genotyped MTHFR 677C > T and MTHFR 1298A > C in a population-based study of bladder cancer of 352 patients and 551 controls from New Hampshire, USA.
|
16217917 |
2005 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
The MTHFR gene C677T and A1298C polymorphisms were associated with an increased risk of bladder cancer in our population (For the MTHFR gene C677T polymorphism and A1298C polymorphism; p=0.036<0.05; p=0.278>0.05 respectively).
|
22126575 |
2011 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.
|
23773402 |
2013 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
The results from the current update analysis suggest that C677T and A1298C polymorphisms in the MTHFR gene are associated with bladder cancer risk and prognosis.
|
22296361 |
2011 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Results from the current update analysis suggested that the C677T and A1298C polymorphisms in the MTHFR gene were associated with BC risk and disease progression.
|
23578207 |
2013 |
|
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
While the isolated polymorphism C677T did not appear to influence bladder cancer susceptibility, results suggest that it might act with an additive contribution determined by variation at MTHFR A1298C.
|
17574963 |
2007 |